Vertex Pharmaceuticals reported its fourth-quarter fiscal 2024 earnings, revealing an adjusted earnings per share (EPS) of $3.98, which fell short of analysts' expectations of $4.03. The company achieved a revenue of $2.91 billion, exceeding estimates of $2.78 billion and reflecting a year-over-year growth of 15.66%. Despite the strong revenue performance, Vertex's GAAP net loss stood at $536 million, attributed to increased operating expenses. In comparison, the company reported a GAAP net income of $913 million for the quarter. Analysts had anticipated a revenue of $2.78 billion and an EPS of $4.10, indicating a decrease of 2.38% year-over-year in earnings. The growth in revenue was primarily driven by the sales of TRIKAFTA/KAFTRIO, although higher research and development costs impacted overall profitability. For the full fiscal year, Vertex's revenue reached $11.02 billion, marking a 12% increase from the previous year.